Based on a licence from Else Marit Inderberg and Sebastien Wälchli’s group at The Section of Cell Therapy at Oslo University Hospital, the company Zelluna Immunotherapy is developing natural killer cells that are steered by T cell receptors. The aim is to offer different forms of targeted immunotherapy treatments that do not have to be individually tailored for each patient. Zelluna Immunotherapy receives NOK 83 million from investors and the Research Council of Norway to continue its work on this new form of cancer immunotherapy.
Published in major journals, first or last author from Oslo University Hospital.
Genetic loci shared between major depression and intelligence with mixed directions of effect
Nat Hum Behav (in press)
Heart failure and systolic function: time to leave diagnostics based on ejection fraction?
Eur Heart J (in press)
Deep learning and cancer biomarkers: recognising lead-time bias - Authors' reply
Lancet, 397 (10270), 194-195